Clinical trial supply management is the discipline of getting an investigational medicinal product (IMP) — the drug, biologic, or device under study, plus any comparator or placebo — from a GMP-certified manufacturing site into a subject’s hands at the correct dose, correctly blinded, within its validated storage conditions, at the right time, with a documented chain of custody the whole way. It sits at the intersection of pharmaceutical quality (GMP), clinical operations, logistics, and regulatory recordkeeping, and a failure anywhere in that chain — a temperature excursion, a broken blind, a reconciliation discrepancy — can compromise data integrity or trigger a regulatory finding independent of how well the trial itself was designed or conducted.
This guide covers the full IMP supply chain a research administrator, sponsor, or site needs to understand: GMP manufacturing requirements, packaging/labeling and blinding mechanics, the interactive response technology (IRT/IWRS) systems that manage randomization and real-time inventory, cold-chain and temperature-controlled logistics, and the site-level drug accountability and reconciliation obligations that regulators inspect directly.
What clinical trial supply management covers
“Supply” in a trial context is not just shipping. It spans:
- Manufacturing and release — producing the IMP (and, where blinded, the matching comparator/placebo) under Good Manufacturing Practice and formally releasing each batch for clinical use.
- Packaging, labeling, and blinding — converting bulk product into subject- or visit-specific kits, applying trial-compliant labels, and — for blinded designs — obscuring treatment identity in a way that can still be reversed in a defined emergency-unblinding process.
- Distribution and cold-chain logistics — moving product from the manufacturing/packaging site to depots and then to investigator sites (or, in decentralized designs, directly to participants) within its validated temperature range.
- Site-level receipt, storage, dispensing, and accountability — the investigator’s obligation to control, document, and eventually reconcile every unit received.
- Return, destruction, or alternative disposition of unused supply at the end of a subject’s participation or the trial itself.
Every stage generates records a sponsor, monitor, or inspector can be asked to produce — this guide’s regulatory-documentation section below maps out what those records are and why regulators care about them specifically.
GMP manufacturing requirements for investigational medicinal products
IMPs are held to Good Manufacturing Practice requirements, but the framework differs in important ways from GMP for an already-approved, marketed drug — and it differs between the US and EU in how it is codified.
United States: phase-appropriate GMP under 21 CFR Parts 210/211
US current Good Manufacturing Practice for finished drugs is set out in 21 CFR Part 210 and Part 211. Under 21 CFR 210.2(c), however, most Phase 1 investigational drugs are exempt from the full scope of Part 211 — FDA’s 2008 guidance, CGMP for Phase 1 Investigational Drugs, describes a more scaled, phase-appropriate approach for early-phase material. That exemption ends once a drug moves into Phase 2 or 3, or once material from that lot has already been used in a later-phase or marketed product — at that point full Part 211 GMP applies. This “phase-appropriate GMP” concept — quality controls that scale up as a product moves closer to marketing — is a recurring theme across the entire supply chain, not just manufacturing.
API (active pharmaceutical ingredient) manufacturing specifically is governed by ICH Q7, the GMP guideline for APIs first issued by the International Council for Harmonisation in 2000, which also forms the basis for the corresponding EU guidance (EudraLex Volume 4, Part II). The broader ICH quality guideline series — Q8 (pharmaceutical development), Q9 (quality risk management), and Q10 (pharmaceutical quality systems) — collectively defines how quality is meant to be designed into and verified throughout a product’s manufacturing lifecycle, IMP included.
European Union: EU GMP Annex 13 and Annex 16 (QP release)
In the EU, IMP manufacturing has historically been addressed by EU GMP Annex 13, “Manufacture of Investigational Medicinal Products” (EudraLex Volume 4), issued pursuant to the EU Clinical Trials framework — now Regulation (EU) No 536/2014. Annex 13 sets out IMP-specific expectations across quality management, personnel, documentation, production, and quality control, reflecting the greater complexity and variability of investigational manufacturing (frequent formulation changes, small batch sizes, blinding operations) relative to commercial production.
A batch of IMP cannot move to a trial site until a Qualified Person (QP) — a role defined under EU pharmaceutical law and addressed in EU GMP Annex 16 (certification and batch release) — formally certifies that the batch was manufactured and tested in accordance with GMP and the applicable product specification. QP certification is the EU’s functional equivalent of a US batch-release sign-off: the point at which manufacturing quality control formally hands a batch off to clinical supply for distribution.
Packaging, blinding, and randomization: how IRT/IWRS systems manage supply
Most controlled trials require that the treatment assignment be concealed from some combination of the subject, investigator, and sponsor staff (single-, double-, or triple-blind designs). Blinding is enforced largely at the packaging and labeling level: identical-looking kits or containers, over-encapsulation, matching placebo formulation, and randomization codes that map a kit number to a treatment arm without revealing it on the physical product.
The system that manages this mapping — and, in most modern trials, drives supply forecasting and site-level inventory at the same time — is generically called Interactive Response Technology (IRT). Older or narrower terms for essentially the same function still appear throughout the industry: IVRS (Interactive Voice Response System, the original telephone-based version), IWRS (Interactive Web Response System, the web-based successor), and RTSM (Randomization and Trial Supply Management), which emphasizes the supply-chain half of the same platform. A modern IRT/IWRS system typically performs:
- Randomization — assigning enrolled subjects to a treatment arm according to the protocol’s randomization scheme, without human discretion introducing bias.
- Blind maintenance and emergency unblinding — restricting who can see a given subject’s actual assignment, while providing an auditable, protocol-defined pathway for an investigator to break the blind in a genuine safety emergency.
- Kit/inventory management — tracking which physical kit or bottle number is assigned to which subject and visit, so a site dispenses the correct, protocol-compliant unit every time.
- Supply forecasting and resupply — using real-time enrollment and dispensing data to trigger automatic resupply shipments to sites or depots before local inventory runs out or expires, reducing both stock-outs and excess/expired waste.
Because the IRT system effectively holds the randomization code, its own validation, access controls, and audit trail are themselves within regulatory scope — the same electronic-records discipline (21 CFR Part 11 in the US) that applies to a trial’s clinical database applies to the system controlling its blind.
Labeling requirements for investigational products
Labeling is where GMP, blinding, and regulatory documentation intersect directly on the physical product, and the US and EU frameworks differ in specifics.
United States — 21 CFR 312.6: the immediate package of an investigational new drug for human use must carry the statement “Caution: New Drug—Limited by Federal (or United States) law to investigational use.” The label or labeling may not be false or misleading, and specifically may not represent that the investigational drug is safe or effective for the purpose under investigation — a real constraint on how sponsors and CROs can word site- or subject-facing kit labels.
European Union — Annex VI to Regulation (EU) No 536/2014: Annex VI harmonizes IMP and auxiliary medicinal product labeling requirements across EU member states (no further national variation beyond translation). Required elements include the contact details for information on the product, the trial, and emergency unblinding; the substance name and strength; pharmaceutical form, route of administration, and quantity of dosage units; a batch or code number identifying contents and packaging; a clinical trial reference code identifying the trial, site, investigator, and sponsor; and the subject identification number and/or treatment number. A 2022 delegated act amended Annex VI to allow the expiry date to be omitted from the immediate package in defined circumstances where re-labeling itself could compromise product quality or safety — a practical accommodation for long-running trials using re-labeled or extended-shelf-life stock.
Cold-chain and temperature-controlled logistics
Many IMPs — biologics and cell/gene therapies especially, but also a large share of conventional drug products — must be stored and transported within a validated temperature range from the point of manufacture through administration. Losing that range even briefly (a “temperature excursion”) can degrade the product in ways that are not always visually detectable, which is why cold-chain management is treated as a quality-system requirement, not a shipping-logistics afterthought.
In the US, the relevant reference framework is USP General Chapter <1079>, “Good Storage and Distribution Practices for Drug Products,” which defines a risk-based approach to storage and transportation and sets expectations across every link in the chain — manufacturer, distributor, courier, depot, and site — covering temperature mapping and shipping-container qualification, continuous monitoring with alarming, calibration, and staff training. A related sub-chapter, USP <1079.2>, addresses Mean Kinetic Temperature (MKT), a weighted-average calculation used to assess whether a temperature excursion recorded during shipment or storage was significant enough to affect product stability, rather than treating every brief deviation as an automatic failure.
For clinical trial supply specifically, this translates into a standard set of controls: validated shipping qualification for each lane/route, continuous data-logger monitoring on every shipment with defined alarm thresholds, a written excursion-investigation and disposition procedure (does the product remain usable, based on real stability data or MKT analysis, or must it be quarantined/destroyed), and site-level storage equipment (refrigerators, freezers, ultra-low units) that is itself qualified, monitored, and covered by a documented failure-response plan — because a site-level freezer alarm at 2 a.m. is as much a supply-chain event as a customs delay in transit.
Site-level drug accountability and reconciliation
Once IMP arrives at a site, responsibility shifts to the investigator, and this is one of the most heavily inspected elements of trial conduct.
Under US FDA regulation:
- 21 CFR 312.57 requires the sponsor to maintain adequate records of the receipt, shipment, or other disposition of the investigational drug, including the investigator to whom it was shipped and the date, quantity, and batch or code mark of each shipment.
- 21 CFR 312.61 (“Control of the investigational drug”) requires the investigator to administer the drug only to subjects under their own personal supervision or that of a responsible sub-investigator, and prohibits supplying it to any unauthorized person.
- 21 CFR 312.62 (“Investigator recordkeeping and record retention”) requires the investigator to maintain adequate records of the drug’s disposition — dates, quantities, and use by subjects — alongside case histories, and to retain those records for at least 2 years after a marketing application is approved for the studied use, or 2 years after the investigation is discontinued and FDA is notified, whichever applies.
The sponsor is also responsible for ensuring the return of unused supply from any investigator whose participation ends or is terminated, or for authorizing an alternative disposition — provided it does not expose anyone to risk from the drug.
Internationally, ICH E6(R2) Good Clinical Practice, Section 5.14 (“Supplying and Handling Investigational Product(s)”), places closely parallel obligations on the sponsor: confirming all necessary approvals are in place before shipment, ensuring written procedures exist at each site for receipt, storage conditions, dispensing, retrieval of unused product, and its return or destruction, and maintaining systems and records for timely delivery, shipment/receipt/disposition/return/destruction tracking, and product retrieval (including in a recall scenario). The current core guideline, ICH E6(R3) — finalized 6 January 2025, with an EMA effective date of 23 July 2025 for its Principles and Annex 1, and FDA’s own final E6(R3) guidance issued 8 September 2025 — restates this at Section 2.10.1: responsibility for investigational product management, including accountability, handling, dispensing, administration, and return, rests with the investigator, though specific activities may be delegated. E6(R3)’s Annex 2 additionally addresses direct-to-participant shipment and decentralized-trial supply models, an area the original E6(R2) text did not contemplate.
In practice, “reconciliation” is the exercise of comparing what a site received, what it dispensed to specific subjects, what remains on hand, and what was returned or destroyed — and confirming the numbers tie out, unit by unit, kit by kit. A monitor checks this at every routine monitoring visit and again in full at study closeout; a documented, unresolved discrepancy is one of the most common findings in an FDA Bioresearch Monitoring (BIMO) inspection or an equivalent EMA/national-authority audit. Where a site uses IRT for kit dispensing, the system’s own dispensing log provides a real-time electronic record that supplements — but under both FDA and ICH GCP does not by itself replace — the site’s own accountability documentation.
Regulatory documentation and chain of custody
Pulled together, the documentation a sponsor, CRO, or site should expect to produce across the supply chain includes:
- Batch manufacturing and QC release records, and — in the EU — the QP certification confirming GMP/specification compliance before release (Annex 16).
- Shipment records showing chain of custody from manufacturer to depot to site (21 CFR 312.57; ICH E6 5.14/2.10.1).
- Temperature-monitoring data and any excursion investigation/disposition record for each shipment and storage location (USP <1079>/<1079.2>).
- Site-level drug accountability logs recording receipt, dispensing to specific subjects, returns, and destruction (21 CFR 312.61/312.62).
- The randomization/blinding code itself, held securely (typically within the IRT system) with a documented emergency-unblinding procedure.
- Return, reconciliation, and destruction/certificate-of-destruction records at study closeout.
This documentation trail exists for a specific reason: a trial’s efficacy and safety conclusions are only as trustworthy as the product actually administered was known, correctly assigned, and stored within specification. Regulators inspect supply-chain records precisely because a gap here can undermine confidence in the clinical results themselves, independent of how rigorously the trial was otherwise conducted.
Frequently asked questions
What is an IMP (investigational medicinal product)?
An IMP is a pharmaceutical form of an active substance or placebo being tested, or used as a reference, in a clinical trial — including a product with a marketing authorization when used or assembled (formulated or packaged) differently than the authorized form, used for an unauthorized indication, or used to gain further information about an authorized use. It is the EU regulatory term; the US uses “investigational new drug” (or investigational product) in a functionally similar sense under 21 CFR Part 312.
What is the difference between IRT, IWRS, and RTSM?
They describe overlapping generations and emphases of the same underlying technology. IVRS was the original telephone-based system; IWRS is its web-based successor; IRT is the broader, currently standard umbrella term covering randomization, blinding, and supply functions together; RTSM (“Randomization and Trial Supply Management”) is often used interchangeably with IRT but foregrounds the supply-management half specifically. In current industry usage the terms are largely synonymous.
Who is responsible for drug accountability at a trial site?
The investigator. Under both US regulation (21 CFR 312.61/312.62) and ICH GCP (E6(R2) 5.14, E6(R3) 2.10.1), accountability for investigational product at the site — controlling who administers it, and maintaining disposition records — is the investigator’s obligation, though specific administrative tasks may be delegated to qualified site staff. The sponsor separately maintains its own shipment and disposition records under 21 CFR 312.57 and the equivalent ICH GCP sponsor obligations.
What counts as a reportable temperature excursion?
There is no single universal numeric threshold — it depends on the specific product’s validated stability data. USP <1079>/<1079.2>’s Mean Kinetic Temperature methodology is the standard tool for assessing whether a given excursion, based on its duration and magnitude, is likely to have affected product stability, rather than treating every deviation from the labeled storage range as an automatic failure. A written, protocol- and product-specific excursion-management procedure — defining monitoring frequency, alarm thresholds, and the investigation/disposition decision — should exist before shipping begins, not be improvised after the first alarm fires.
How long must investigator drug-accountability records be retained?
Under 21 CFR 312.62, at least 2 years after a marketing application is approved for the studied indication, or 2 years after the investigation is discontinued and FDA has been notified — whichever applies. Institutional or sponsor contractual retention requirements are frequently longer than this regulatory floor, so the applicable clinical trial agreement should always be checked rather than assuming the FDA minimum controls.
Related CASRAI resources
For adjacent topics not covered in depth here, see CASRAI’s guides on Good Manufacturing Practice (GMP), clinical data management, what counts as an NIH-defined clinical trial, clinical trial registration and reporting compliance, and informed consent in research; and the dictionary entries for ICH GCP and informed consent. For the wider clinical research administration picture, see the Clinical Research Administration cluster hub.
